Literature DB >> 2894817

Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project.

T A Kurzynski1, D M Boehm, J A Rott-Petri, R F Schell, P E Allison.   

Abstract

MICs for 90% (MIC90s) of 75 Bordetella pertussis strains for amoxicillin, erythromycin, rifampin, and sulfamethoxazole-trimethoprim were 1, less than or equal to 0.12, 1, and 4 micrograms/ml, respectively. Susceptibility rates were all greater than or equal to 93%. Only 17% of the strains were susceptible to tetracycline. The MIC90s of ciprofloxacin, enoxacin, norfloxacin, ofloxacin, and roxithromycin were less than or equal to 0.06, 0.5, 0.25, 0.12, and 0.5 micrograms/ml, respectively. For B. parapertussis, the MIC90s were 16-fold higher with amoxicillin and rifampin and 2- to 4-fold higher with the fluoroquinolones and roxithromycin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894817      PMCID: PMC172115          DOI: 10.1128/AAC.32.1.137

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Proposed disk diffusion susceptibility criteria for ofloxacin.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

2.  Epidemics of parapertussis. 20 years' observations in Denmark.

Authors:  H Lautrop
Journal:  Lancet       Date:  1971-06-12       Impact factor: 79.321

3.  Susceptibility of Bordetella pertussis to nine antimicrobial agents.

Authors:  J W Bass; F W Crast; J B Kotheimer; I A Mitchell
Journal:  Am J Dis Child       Date:  1969-03

4.  Antibiotic resistance of degraded strains of Bordetella pertussis.

Authors:  R M Bannatyne; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin.

Authors:  G Zackrisson; J E Brorson; B Björnegård; B Trollfors
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

6.  Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland.

Authors:  J Mertsola
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

7.  Bordetella parapertussis. Recent experience and a review of the literature.

Authors:  C C Linnemann; E B Perry
Journal:  Am J Dis Child       Date:  1977-05

8.  In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.

Authors:  J T Rudrik; S J Cavalieri; E M Britt
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Bordetella bronchiseptica bronchitis.

Authors:  C J Papasian; N J Downs; R L Talley; D J Romberger; G R Hodges
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

10.  Demonstration of R factors in Bordetella bronchiseptica isolated from pigs.

Authors:  N Terakado; H Azechi; K Ninomiya; T Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1973-05       Impact factor: 5.191

View more
  19 in total

1.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.

Authors:  J E Hoppe; C G Simon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

3.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.

Authors:  J E Hoppe; A Dalhoff; D Pfründer
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

4.  Update of epidemiology, diagnosis, and treatment of pertussis.

Authors:  J E Hoppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

5.  Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.

Authors:  J E Hoppe; A Eichhorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

6.  Isolation of Bordetella bronchiseptica from blood and a pancreatic abscess.

Authors:  Nancy A Matic; Paul E Bunce
Journal:  J Clin Microbiol       Date:  2015-03-04       Impact factor: 5.948

7.  In vitro susceptibility of Bordetella parapertussis to various antimicrobial agents.

Authors:  M Watanabe; Y Haraguchi
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  Antimicrobial susceptibility of Bordetella avium and Bordetella bronchiseptica isolates.

Authors:  J E Mortensen; A Brumbach; T R Shryock
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

9.  Comparison of modified Bordet-Gengou and modified Regan-Lowe media for the isolation of Bordetella pertussis and Bordetella parapertussis.

Authors:  T A Kurzynski; D M Boehm; J A Rott-Petri; R F Schell; P E Allison
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

Review 10.  Human infections associated with Bordetella bronchiseptica.

Authors:  B F Woolfrey; J A Moody
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.